Insight from Excellence First Enterprise Consultancy (EFEC)
Disclaimer: This article is for general information only and does not constitute professional, financial, or legal advice. Market projections are based on current data and subject to change.
China’s healthcare digitisation just took a major leap forward — and UK life sciences companies have a rare early-mover window to seize.
On 1 January 2026, China will implement GB/T 45938—2025, its first national medical insurance standard. This landmark framework sets unified technical requirements for digital health services across the country, creating a market opportunity valued at £145 billion.
For UK firms with expertise in digital health, medical technology, AI-enabled diagnostics, and healthcare IT, this is more than a policy update — it’s a market-defining shift.
Through its IN2China services, Cambridge-based Excellence First Enterprise Consultancy (EFEC) has been helping UK innovators navigate China’s fast-changing healthcare environment. Here’s our take on what GB/T 45938—2025 means for UK businesses and how to position for success.
What the New Standard Covers
GB/T 45938—2025, officially titled Medical Security Information Platform Convenient Service Technical Specification, sets out nationwide technical rules for four key services:
- Medical Insurance Electronic Certificate (医保码)
- A unified QR code-based identity system for medical insurance.
- Already activated by 1.12 billion people and accepted in 800,000+ healthcare institutions.
- Medical Insurance Mobile Payment
- Integrated, real-time settlement across 4.7 million institutions.
- Electronic Medical Prescriptions
- Used in over 350,000 healthcare institutions with more than 63 million prescriptions issued digitally.
- Personal Medical Insurance Information Authorisation
- Secure protocols for patient data access and sharing.
This is the largest digital health identity system in the world — and now it will run on a single, enforceable standard.
The Market in Numbers
- £145bn: Combined opportunity in digital health, AI healthcare, and medical insurance tech.
- 16.8% CAGR: Projected growth of China’s digital healthcare market through 2033.
- 40% annual growth: Spending on innovative drugs during China’s current Five-Year Plan.
- 95%: Insurance coverage across 1.32 billion people.
By 2025, China’s digital healthcare market will be worth ~£45bn, with the AI healthcare segment expected to grow from $1.6bn in 2023 to $16bn by 2028.
Why This Matters for UK Companies
China’s “Healthy China 2030” agenda is driving investment in:
- Infectious disease control and prevention systems.
- Chronic disease management for an ageing population (28% over 60 by 2040).
- Digital health infrastructure and interoperability.
- AI-enabled diagnostics and telemedicine.
For UK firms, the high-priority areas include:
- Digital Health Infrastructure: EMR interoperability, cloud solutions, healthcare analytics.
- AI-Driven Healthcare: Precision medicine, imaging diagnostics, predictive analytics.
- Regulatory Technology: Compliance management, encryption, privacy-preserving computation.
- Telemedicine and Remote Care: Remote monitoring, digital therapeutics, patient engagement tools.
Investment and Partnership Signals
The environment is warming for UK-China collaborations:
- Government Support: UK ranks third globally for life sciences equity finance, after the US and China.
- Strategic Investment: China Medical System (CMS) has pledged £25m for UK biotech over five years.
- Innovation Hubs: Free Trade Zones in Beijing, Shanghai, Guangdong, and Hainan fast-track R&D in stem cells, gene therapy, and diagnostics.
For Cambridge-area startups and spinouts, this is fertile ground for cross-border scale-up.
Navigating the Regulatory Landscape
UK companies must ensure compliance with China’s GB standards (Guobiao) and potentially secure CNAS certification. Key requirements include:
- Interface specs for third-party integration.
- Performance benchmarks for speed and reliability.
- Encryption, authentication, and privacy safeguards.
- Interoperability across platforms.
Data protection is equally critical. The Personal Information Protection Law and Data Security Law create demand for privacy tech — from federated learning systems to blockchain-secured records.
How to Position for Success
- Lead with Partnerships
Work with established Chinese partners to navigate regulation, procurement, and cultural norms. EFEC’s IN2China platform specialises in matching UK innovators with high-value Chinese collaborators. - Focus Regionally
The Yangtze River Delta (Shanghai, Suzhou, Hangzhou) remains the most mature life sciences ecosystem for international players. However, other regions are also stepping up:
- Beijing — China’s policy, regulatory, and research hub, home to the NMPA, top universities, and major biotech clusters in Zhongguancun Life Science Park and the Beijing Economic-Technological Development Area.
- Guangdong — Guangzhou’s Biotech Island and surrounding innovation districts have attracted 500+ life sciences firms, including global names like AstraZeneca, backed by strong provincial R&D incentives.
- Wuhan — Biolake in Optics Valley is a fast-growing biomedical industrial base with six specialised subsectors, supported by funding, incubators, and infrastructure.
- Sichuan–Chongqing — Chengdu’s Tianfu Bio-Town, precision medicine initiatives, and the Sichuan–Chongqing biomedicine innovation corridor are linking over 100 joint projects from lab to clinic.
- Build Standards-Ready Solutions
Design products that integrate seamlessly with China’s medical insurance platform and the four core GB/T 45938 service categories. - Embed AI and Interoperability
China’s AI regulations, such as the Interim Measures for Generative AI Services, are supportive of healthcare AI. Solutions that solve “information silo” issues will be especially valued.
The Clock is Ticking
January 2026 is the go-live date. The early movers will be those who:
- Understand the standard’s technical demands.
- Adapt their products for GB compliance.
- Secure trusted partners before the market saturates.
With China’s healthcare market projected to hit $328.8 bn by 2033, the UK’s research excellence and regulatory credibility can unlock global-scale impact.
About EFEC
Excellence First Enterprise Consultancy (EFEC) is a UK-based specialist in UK–China life sciences collaboration. Through our IN2China services, we help companies build strategic partnerships, align with local regulations, and accelerate market entry.